D T Beattie

Summary

Affiliation: Theravance Inc
Country: USA

Publications

  1. ncbi The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo
    D T Beattie
    Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Br J Pharmacol 143:549-60. 2004
  2. ncbi The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone
    D T Beattie
    Department of Pharmacology, Theravance Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Naunyn Schmiedebergs Arch Pharmacol 375:205-20. 2007
  3. ncbi Serotonin pharmacology in the gastrointestinal tract: a review
    D T Beattie
    Pharmacology Department, Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Naunyn Schmiedebergs Arch Pharmacol 377:181-203. 2008
  4. ncbi The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity
    D T Beattie
    Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA, 94080, USA
    Naunyn Schmiedebergs Arch Pharmacol 378:139-47. 2008
  5. ncbi The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity
    J A M Smith
    Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA, 94080, USA
    Naunyn Schmiedebergs Arch Pharmacol 378:125-37. 2008
  6. ncbi A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptors
    R G Vickery
    Department of Molecular and Cell Biology, Theravance Inc, South San Francisco, CA 94080, USA
    Br J Pharmacol 150:782-91. 2007
  7. ncbi The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat
    J L McCullough
    Department of Pharmacology, Theravance Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Pharmacol Res 53:353-8. 2006
  8. ncbi Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
    C W Rittershaus
    AVANT Immunotherapeutics, Inc, Needham, MA 02494, USA
    Arterioscler Thromb Vasc Biol 20:2106-12. 2000
  9. ncbi Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study
    M Goldberg
    Theravance, Inc, South San Francisco, CA 94080, USA
    Aliment Pharmacol Ther 32:1102-12. 2010
  10. ncbi The influence of the trigeminal ganglion on carotid blood flow in anaesthetized guinea-pigs
    D T Beattie
    Pharmacology II, Glaxo Research and Development Ltd, Ware, Herts
    Br J Pharmacol 112:262-6. 1994

Collaborators

  • J A M Smith
  • S S Hegde
  • A W Mangel
  • M Goldberg
  • R G Vickery
  • J L McCullough
  • Y P Li
  • O Daniels
  • C W Rittershaus
  • J F Johanson
  • M Kitt
  • K Kersey
  • P P A Humphrey
  • T Pulido-Rios
  • E Kaufman
  • N Mai
  • T Pulido Rios
  • S R Armstrong
  • C D Emmett
  • D P Miller
  • U S Ryan
  • A D Callow
  • H C Marsh
  • M D Picard
  • C L Pettey
  • L J Thomas
  • R A Hammond
  • H Adari
  • C M Honan

Detail Information

Publications10

  1. ncbi The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo
    D T Beattie
    Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Br J Pharmacol 143:549-60. 2004
    ..It remains to be determined whether this 5-HT2B receptor antagonist activity of tegaserod contributes to its clinical profile...
  2. ncbi The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone
    D T Beattie
    Department of Pharmacology, Theravance Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Naunyn Schmiedebergs Arch Pharmacol 375:205-20. 2007
    ..The clinical significance of the data from this study remains to be determined...
  3. ncbi Serotonin pharmacology in the gastrointestinal tract: a review
    D T Beattie
    Pharmacology Department, Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Naunyn Schmiedebergs Arch Pharmacol 377:181-203. 2008
    ....
  4. ncbi The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity
    D T Beattie
    Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA, 94080, USA
    Naunyn Schmiedebergs Arch Pharmacol 378:139-47. 2008
    ..The selective 5-HT(4) receptor agonist, TD-5108, demonstrates robust in vivo activity in the guinea pig, rat and dog gastrointestinal tracts...
  5. ncbi The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity
    J A M Smith
    Theravance, Inc, 901 Gateway Boulevard, South San Francisco, CA, 94080, USA
    Naunyn Schmiedebergs Arch Pharmacol 378:125-37. 2008
    ..The high intrinsic activity and preferential binding of TD-5108 to 5-HT4 over other 5-HT receptors may result in an improved clinical profile for the treatment of gastrointestinal disorders of reduced motility...
  6. ncbi A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptors
    R G Vickery
    Department of Molecular and Cell Biology, Theravance Inc, South San Francisco, CA 94080, USA
    Br J Pharmacol 150:782-91. 2007
    ..The functional properties of guinea-pig 5-HT(4(b)) receptors were compared with native receptors in guinea-pig colon...
  7. ncbi The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat
    J L McCullough
    Department of Pharmacology, Theravance Inc, 901 Gateway Boulevard, South San Francisco, CA 94080, USA
    Pharmacol Res 53:353-8. 2006
    ..The clinical relevance of the 5-HT2B receptor antagonism of tegaserod remains to be determined...
  8. ncbi Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
    C W Rittershaus
    AVANT Immunotherapeutics, Inc, Needham, MA 02494, USA
    Arterioscler Thromb Vasc Biol 20:2106-12. 2000
    ..In addition, these studies suggest that vaccination against a self-antigen is a viable therapeutic strategy for disease management...
  9. ncbi Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study
    M Goldberg
    Theravance, Inc, South San Francisco, CA 94080, USA
    Aliment Pharmacol Ther 32:1102-12. 2010
    ..Velusetrag is an orally active 5-HT(4) receptor agonist of potential benefit in treating chronic idiopathic constipation...
  10. ncbi The influence of the trigeminal ganglion on carotid blood flow in anaesthetized guinea-pigs
    D T Beattie
    Pharmacology II, Glaxo Research and Development Ltd, Ware, Herts
    Br J Pharmacol 112:262-6. 1994
    ..The transmitter mediating this effect is most likely to be VIP...